Drug, Cosmetic & Toiletry Wholesaling in the US - Industry Research Report

Feeling refreshed: Increased expenditure for prescription and OTC drugs will support the industry

The success of the Drug, Cosmetic and Toiletry Wholesaling industry is driven by demand for its primary product segment, pharmaceuticals. With several major brand-name drugs losing patent exclusivity, new opportunities have been created for less expensive generic drugs on the market. Nonetheless, wholesalers have countered by adjusting their prices and supplies accordingly. As a result, industry revenue will rise a CAGR of 3.1% to $1.4 trillion over the five years to 2023. The COVID-19 pandemic has boosted demand for products as hospitalization rates skyrocketed in 2020 and 2021. In 2023 alone, industry revenue will increase 2.2%.

Drug, cosmetic and toiletry wholesalers primarily distribute pharmaceutical products intended for internal and external consumption, such as tablets, capsules, vials, ointments and powders. The industry includes a range of biological and medical products, in addition to botanical drugs and herbs. The industry does not include businesses that primarily distribute surgical, dental or hospital equipment.

This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.